2310 related articles for article (PubMed ID: 8292896)
1. Changes in plasma 5-S-cysteinyldopa concentration in B16 melanoma-bearing mice treated with interferon-beta or dacarbazine.
Hasegawa K; Inoue S; Wakamatsu K; Ito S; Fujita K; Ishihara K
Melanoma Res; 1993 Oct; 3(5):377-80. PubMed ID: 8292896
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
[TBL] [Abstract][Full Text] [Related]
3. Melanin-related metabolites in urine of B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1988; 68(5):385-9. PubMed ID: 2461020
[TBL] [Abstract][Full Text] [Related]
4. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma.
Kiyohara E; Tamai K; Katayama I; Kaneda Y
Gene Ther; 2012 Jul; 19(7):734-41. PubMed ID: 21900962
[TBL] [Abstract][Full Text] [Related]
5. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice.
Hu F; Woodward WR; Peterson LL
J Invest Dermatol; 1988 Feb; 90(2):149-51. PubMed ID: 3123557
[TBL] [Abstract][Full Text] [Related]
6. Research on the anti-tumour effect of steroid lactam alkylator (NSC-294859) in comparison with conventional chemotherapeutics in malignant melanoma.
Trafalis DT; Camoutsis C; Papageorgiou A
Melanoma Res; 2005 Aug; 15(4):273-81. PubMed ID: 16034305
[TBL] [Abstract][Full Text] [Related]
7. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
[TBL] [Abstract][Full Text] [Related]
8. B16 and cloudman S91 mouse melanoma cells susceptibility to apoptosis after dacarbazine treatment.
Olszewska-Słonina DM; Styczyńisk J; Drewa TA; Olszewski KJ; Czajkowski R
Acta Pol Pharm; 2005; 62(6):473-83. PubMed ID: 16583988
[TBL] [Abstract][Full Text] [Related]
9. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
10. Ethanol extract of Ilex hainanensis Merr. exhibits anti-melanoma activity by induction of G
Zhang YQ; Yang H; Sun WD; Wang J; Zhang BY; Shen YJ; Yin MQ; Liu YX; Liu C; Sun Y
Chin J Integr Med; 2018 Jan; 24(1):47-55. PubMed ID: 28741062
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth.
Hervieu A; Rébé C; Végran F; Chalmin F; Bruchard M; Vabres P; Apetoh L; Ghiringhelli F; Mignot G
J Invest Dermatol; 2013 Feb; 133(2):499-508. PubMed ID: 22951720
[TBL] [Abstract][Full Text] [Related]
13. Treatment of malignant melanoma with dacarbazin (DTIC-DOME) with special reference to urinary excretion of 5-S-cysteinyldopa.
Jönsson PE; Agrup G; Arnbjörnsson E; Hafström L; Rorsman H
Cancer; 1980 Jan; 45(2):245-8. PubMed ID: 6153150
[TBL] [Abstract][Full Text] [Related]
14. Gold(III) porphyrin 1a prolongs the survival of melanoma-bearing mice and inhibits angiogenesis.
Lum CT; Huo L; Sun RW; Li M; Kung HF; Che CM; Lin MC
Acta Oncol; 2011 Jun; 50(5):719-26. PubMed ID: 21110776
[TBL] [Abstract][Full Text] [Related]
15. Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
Szende B; Horváth A; Bökönyi G; Kéri G
Br J Cancer; 2003 Jan; 88(1):132-6. PubMed ID: 12556972
[TBL] [Abstract][Full Text] [Related]
16. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
Chabot GG; Flaherty LE; Valdivieso M; Baker LH
Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model.
Wack C; Becker JC; Bröcker EB; Lutz WK; Fischer WH
Melanoma Res; 2001 Jun; 11(3):247-53. PubMed ID: 11468513
[TBL] [Abstract][Full Text] [Related]
18. PTD4-apoptin protein and dacarbazine show a synergistic antitumor effect on B16-F1 melanoma in vitro and in vivo.
Jin JL; Gong J; Yin TJ; Lu YJ; Xia JJ; Xie YY; Di Y; He L; Guo JL; Sun J; Noteborn MH; Qu S
Eur J Pharmacol; 2011 Mar; 654(1):17-25. PubMed ID: 21184754
[TBL] [Abstract][Full Text] [Related]
19. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1990; 70(5):367-72. PubMed ID: 1980967
[TBL] [Abstract][Full Text] [Related]
20. Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice.
Thallinger C; Skorjanec S; Soleiman A; Tzaneva S; Griss J; Rous W; Poeppl W; Weinlich G; Karimian-Teherani D; Joukhadar C
Pharmacology; 2008; 82(3):233-8. PubMed ID: 18810248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
